HAMILTON, Bermuda, Nov. 4, 2015 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at three investor conferences:
- November 11 at 4:30 p.m. ET at the Credit Suisse 24th annual Healthcare Conference
- November 19 at 8:20 a.m. ET at the Jefferies Autumn 2015 Global Healthcare Conference
- December 2 at 9:00 a.m. ET at the Piper Jaffray 27th Annual Healthcare Conference
Axovant's management team will present an overview of the recently announced expansion of its dementia drug development pipeline with the acquisition of nelotanserin and the addition of three new clinical programs to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S.
In addition, an update will be provided on the Company's global, multi-center, double-blind, placebo-controlled confirmatory Phase 3 study of RVT-101 for the treatment of mild-to-moderate Alzheimer's disease called the MINDSET Study. For more information about the MINDSET study please visit www.alzheimersglobalstudy.com, email firstname.lastname@example.org or call 646-495-8197.
A simultaneous webcast can be accessed by visiting the Investors section of www.axovant.com and selecting Events and Presentations. Replays will be available for 30 days following each conference.
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral components of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the disease.
SOURCE Axovant Sciences Ltd.